APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease CDMO

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurodegenerative Disease CDMO Industry Growth and Trends Forecast to 2032

15 April 2026112 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease CDMO Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease CDMO Market Analysis and Forecast 2026-2032258 pages · $4,950 USD

Market perspective

According to APO Research, the global Neurodegenerative Disease CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Neurodegenerative Disease CDMO market include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai and Fujirebio Holdings, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurodegenerative Disease CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurodegenerative Disease CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurodegenerative Disease CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurodegenerative Disease CDMO.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Neurodegenerative Disease CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurodegenerative Disease CDMO Market by Company

AC Immune

Alterity Therapeutics

Biogen

Charles River Laboratories

Coave Therapeutics

Sysmex Corp

Donanemab

Eisai

Fujirebio Holdings

GenSight Biologics

Neuropore Therapies

Nevrargenics

PPD

Samsung Biologics

Sanofi(Vigil Neuroscience)

Neurodegenerative Disease CDMO Segment by Type

Small Molecule Drug CDMO

Biopharmaceutical CDMO

Cell and Gene Therapy (CGT) CDMO

OtherS

Neurodegenerative Disease CDMO Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Neurodegenerative Disease CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease CDMO Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Neurodegenerative Disease CDMO Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Neurodegenerative Disease CDMO Market Share by Region (2021-2026) Table 4. Global Neurodegenerative Disease CDMO Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Neurodegenerative Disease CDMO Market Share by Region (2027-2032) Table 6. Global Neurodegenerative Disease CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Neurodegenerative Disease CDMO Market Size Share by Type (2021-2026) Table 9. Global Neurodegenerative Disease CDMO Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Neurodegenerative Disease CDMO Market Size Share Forecasted by Type (2027-2032) Table 11. North America Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Neurodegenerative Disease CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Neurodegenerative Disease CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Neurodegenerative Disease CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Neurodegenerative Disease CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Neurodegenerative Disease CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Neurodegenerative Disease CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Neurodegenerative Disease CDMO Market Size Share by Application (2021-2026) Table 24. Global Neurodegenerative Disease CDMO Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Neurodegenerative Disease CDMO Market Size Share Forecasted by Application (2027-2032) Table 26. North America Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Neurodegenerative Disease CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Neurodegenerative Disease CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Neurodegenerative Disease CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Neurodegenerative Disease CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Neurodegenerative Disease CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Neurodegenerative Disease CDMO Industry Trends Table 37. Neurodegenerative Disease CDMO Industry Drivers Table 38. Neurodegenerative Disease CDMO Industry Opportunities and Challenges Table 39. Neurodegenerative Disease CDMO Industry Restraints Table 40. Global Neurodegenerative Disease CDMO Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Neurodegenerative Disease CDMO Revenue Market Share by Company (2021-2026) Table 42. Global Neurodegenerative Disease CDMO Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Neurodegenerative Disease CDMO Key Company Headquarters & Area Served Table 44. Global Neurodegenerative Disease CDMO Company, Product Type & Application Table 45. Global Neurodegenerative Disease CDMO Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Neurodegenerative Disease CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. AC Immune Company Information Table 49. AC Immune Business Overview Table 50. AC Immune Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. AC Immune Neurodegenerative Disease CDMO Product Portfolio Table 52. AC Immune Recent Development Table 53. Alterity Therapeutics Company Information Table 54. Alterity Therapeutics Business Overview Table 55. Alterity Therapeutics Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 57. Alterity Therapeutics Recent Development Table 58. Biogen Company Information Table 59. Biogen Business Overview Table 60. Biogen Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Biogen Neurodegenerative Disease CDMO Product Portfolio Table 62. Biogen Recent Development Table 63. Charles River Laboratories Company Information Table 64. Charles River Laboratories Business Overview Table 65. Charles River Laboratories Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio Table 67. Charles River Laboratories Recent Development Table 68. Coave Therapeutics Company Information Table 69. Coave Therapeutics Business Overview Table 70. Coave Therapeutics Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 72. Coave Therapeutics Recent Development Table 73. Sysmex Corp Company Information Table 74. Sysmex Corp Business Overview Table 75. Sysmex Corp Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio Table 77. Sysmex Corp Recent Development Table 78. Donanemab Company Information Table 79. Donanemab Business Overview Table 80. Donanemab Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Donanemab Neurodegenerative Disease CDMO Product Portfolio Table 82. Donanemab Recent Development Table 83. Eisai Company Information Table 84. Eisai Business Overview Table 85. Eisai Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Eisai Neurodegenerative Disease CDMO Product Portfolio Table 87. Eisai Recent Development Table 88. Fujirebio Holdings Company Information Table 89. Fujirebio Holdings Business Overview Table 90. Fujirebio Holdings Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio Table 92. Fujirebio Holdings Recent Development Table 93. GenSight Biologics Company Information Table 94. GenSight Biologics Business Overview Table 95. GenSight Biologics Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio Table 97. GenSight Biologics Recent Development Table 98. Neuropore Therapies Company Information Table 99. Neuropore Therapies Business Overview Table 100. Neuropore Therapies Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio Table 102. Neuropore Therapies Recent Development Table 103. Nevrargenics Company Information Table 104. Nevrargenics Business Overview Table 105. Nevrargenics Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Nevrargenics Neurodegenerative Disease CDMO Product Portfolio Table 107. Nevrargenics Recent Development Table 108. PPD Company Information Table 109. PPD Business Overview Table 110. PPD Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. PPD Neurodegenerative Disease CDMO Product Portfolio Table 112. PPD Recent Development Table 113. Samsung Biologics Company Information Table 114. Samsung Biologics Business Overview Table 115. Samsung Biologics Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio Table 117. Samsung Biologics Recent Development Table 118. Sanofi(Vigil Neuroscience) Company Information Table 119. Sanofi(Vigil Neuroscience) Business Overview Table 120. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio Table 122. Sanofi(Vigil Neuroscience) Recent Development Table 123. North America Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. North America Neurodegenerative Disease CDMO Market Size by Country (2021-2026) & (US$ Million) Table 125. North America Neurodegenerative Disease CDMO Market Share by Country (2021-2026) Table 126. North America Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. North America Neurodegenerative Disease CDMO Market Share Forecast by Country (2027-2032) Table 128. Europe Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Europe Neurodegenerative Disease CDMO Market Size by Country (2021-2026) & (US$ Million) Table 130. Europe Neurodegenerative Disease CDMO Market Share by Country (2021-2026) Table 131. Europe Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Europe Neurodegenerative Disease CDMO Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Neurodegenerative Disease CDMO Market Size by Country (2021-2026) & (US$ Million) Table 135. Asia-Pacific Neurodegenerative Disease CDMO Market Share by Country (2021-2026) Table 136. Asia-Pacific Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Asia-Pacific Neurodegenerative Disease CDMO Market Share Forecast by Country (2027-2032) Table 138. Latin America Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Latin America Neurodegenerative Disease CDMO Market Size by Country (2021-2026) & (US$ Million) Table 140. Latin America Neurodegenerative Disease CDMO Market Share by Country (2021-2026) Table 141. Latin America Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Latin America Neurodegenerative Disease CDMO Market Share Forecast by Country (2027-2032) Table 143. Middle East & Africa Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East & Africa Neurodegenerative Disease CDMO Market Share by Country (2021-2026) Table 146. Middle East & Africa Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East & Africa Neurodegenerative Disease CDMO Market Share Forecast by Country (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Neurodegenerative Disease CDMO Product Image Figure 3. Global Neurodegenerative Disease CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 5. Global Neurodegenerative Disease CDMO Market Share by Region: 2025 VS 2032 Figure 6. Global Neurodegenerative Disease CDMO Market Share by Region (2021-2032) Figure 7. North America Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Small Molecule Drug CDMO Image Figure 13. Global Small Molecule Drug CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Biopharmaceutical CDMO Image Figure 15. Global Biopharmaceutical CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Cell and Gene Therapy (CGT) CDMO Image Figure 17. Global Cell and Gene Therapy (CGT) CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. OtherS Image Figure 19. Global OtherS Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Neurodegenerative Disease CDMO Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Neurodegenerative Disease CDMO Market Share by Type 2025 VS 2032 Figure 22. North America Neurodegenerative Disease CDMO Market Size Share by Type (2021-2032) Figure 23. Europe Neurodegenerative Disease CDMO Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Neurodegenerative Disease CDMO Market Size Share by Type (2021-2032) Figure 25. Latin America Neurodegenerative Disease CDMO Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Neurodegenerative Disease CDMO Market Size Share by Type (2021-2032) Figure 27. Alzheimer's Disease Image Figure 28. Global Alzheimer's Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Parkinson's Disease Image Figure 30. Global Parkinson's Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Huntington's Disease Image Figure 32. Global Huntington's Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Amyotrophic Lateral Sclerosis (ALS) Image Figure 34. Global Amyotrophic Lateral Sclerosis (ALS) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Multiple System Atrophy (MSA) Image Figure 36. Global Multiple System Atrophy (MSA) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Progressive Supranuclear Palsy (PSP) Image Figure 38. Global Progressive Supranuclear Palsy (PSP) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Others Image Figure 40. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Global Neurodegenerative Disease CDMO Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Neurodegenerative Disease CDMO Market Share by Application 2025 VS 2032 Figure 43. North America Neurodegenerative Disease CDMO Market Size Share by Application (2021-2032) Figure 44. Europe Neurodegenerative Disease CDMO Market Size Share by Application (2021-2032) Figure 45. Asia-Pacific Neurodegenerative Disease CDMO Market Size Share by Application (2021-2032) Figure 46. Latin America Neurodegenerative Disease CDMO Market Size Share by Application (2021-2032) Figure 47. Middle East and Africa Neurodegenerative Disease CDMO Market Size Share by Application (2021-2032) Figure 48. Global Top 5 and 10 Neurodegenerative Disease CDMO Players Market Share by Revenue in 2025 Figure 49. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 50. North America Neurodegenerative Disease CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. North America Neurodegenerative Disease CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. North America Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 53. Europe Neurodegenerative Disease CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Neurodegenerative Disease CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 56. Asia-Pacific Neurodegenerative Disease CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Asia-Pacific Neurodegenerative Disease CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Asia-Pacific Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 59. Latin America Neurodegenerative Disease CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Neurodegenerative Disease CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 62. Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Middle East & Africa Neurodegenerative Disease CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 64. Middle East & Africa Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule Drug CDMO
  • Biopharmaceutical CDMO
  • Cell and Gene Therapy (CGT) CDMO
  • OtherS
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • AC Immune
  • Alterity Therapeutics
  • Biogen
  • Charles River Laboratories
  • Coave Therapeutics
  • Sysmex Corp
  • Donanemab
  • Eisai
  • Fujirebio Holdings
  • GenSight Biologics
  • Neuropore Therapies
  • Nevrargenics
  • PPD
  • Samsung Biologics
  • Sanofi(Vigil Neuroscience)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Neurodegenerative Disease CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Neurodegenerative Disease CDMO Market Size by Region (2021-2032)
  5. 1.4.1 Global Neurodegenerative Disease CDMO Market Size by Region (2021-2026)
  6. 1.4.2 Global Neurodegenerative Disease CDMO Market Size by Region (2027-2032)
  7. 1.5 Key Regions Neurodegenerative Disease CDMO Market Size (2021-2032)
  8. 1.5.1 North America Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Neurodegenerative Disease CDMO Market Size Growth Rate (2021-2032)
2 Neurodegenerative Disease CDMO Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Small Molecule Drug CDMO
  3. 2.1.2 Biopharmaceutical CDMO
  4. 2.1.3 Cell and Gene Therapy (CGT) CDMO
  5. 2.1.4 OtherS
  6. 2.2 Global Neurodegenerative Disease CDMO Market Size by Type
  7. 2.2.1 Global Neurodegenerative Disease CDMO Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Neurodegenerative Disease CDMO Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Neurodegenerative Disease CDMO Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Neurodegenerative Disease CDMO Market Size by Regions
  11. 2.3.1 North America Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Neurodegenerative Disease CDMO Market Size Breakdown by Type (2021-2026)
3 Neurodegenerative Disease CDMO Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Alzheimer's Disease
  3. 3.1.2 Parkinson's Disease
  4. 3.1.3 Huntington's Disease
  5. 3.1.4 Amyotrophic Lateral Sclerosis (ALS)
  6. 3.1.5 Multiple System Atrophy (MSA)
  7. 3.1.6 Progressive Supranuclear Palsy (PSP)
  8. 3.1.7 Others
  9. 3.2 Global Neurodegenerative Disease CDMO Market Size by Application
  10. 3.2.1 Global Neurodegenerative Disease CDMO Market Size Overview by Application (2021-2032)
  11. 3.2.2 Global Neurodegenerative Disease CDMO Historic Market Size Review by Application (2021-2026)
  12. 3.2.3 Global Neurodegenerative Disease CDMO Market Size Forecasted by Application (2027-2032)
  13. 3.3 Global Neurodegenerative Disease CDMO Market Size by Regions
  14. 3.3.1 North America Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026)
  15. 3.3.2 Europe Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026)
  16. 3.3.3 Asia-Pacific Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026)
  17. 3.3.4 South America Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026)
  18. 3.3.5 Middle East and Africa Neurodegenerative Disease CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Neurodegenerative Disease CDMO Industry Trends
  2. 4.2 Neurodegenerative Disease CDMO Industry Drivers
  3. 4.3 Neurodegenerative Disease CDMO Industry Opportunities and Challenges
  4. 4.4 Neurodegenerative Disease CDMO Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Neurodegenerative Disease CDMO Revenue (2021-2026)
  2. 5.2 Global Neurodegenerative Disease CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Neurodegenerative Disease CDMO Key Company Headquarters & Area Served
  4. 5.4 Global Neurodegenerative Disease CDMO Company, Product Type & Application
  5. 5.5 Global Neurodegenerative Disease CDMO Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Neurodegenerative Disease CDMO Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Neurodegenerative Disease CDMO Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Neurodegenerative Disease CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 AC Immune
  2. 6.1.1 AC Immune Company Information
  3. 6.1.2 AC Immune Business Overview
  4. 6.1.3 AC Immune Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 AC Immune Neurodegenerative Disease CDMO Product Portfolio
  6. 6.1.5 AC Immune Recent Developments
  7. 6.2 Alterity Therapeutics
  8. 6.2.1 Alterity Therapeutics Company Information
  9. 6.2.2 Alterity Therapeutics Business Overview
  10. 6.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  12. 6.2.5 Alterity Therapeutics Recent Developments
  13. 6.3 Biogen
  14. 6.3.1 Biogen Company Information
  15. 6.3.2 Biogen Business Overview
  16. 6.3.3 Biogen Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Biogen Neurodegenerative Disease CDMO Product Portfolio
  18. 6.3.5 Biogen Recent Developments
  19. 6.4 Charles River Laboratories
  20. 6.4.1 Charles River Laboratories Company Information
  21. 6.4.2 Charles River Laboratories Business Overview
  22. 6.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio
  24. 6.4.5 Charles River Laboratories Recent Developments
  25. 6.5 Coave Therapeutics
  26. 6.5.1 Coave Therapeutics Company Information
  27. 6.5.2 Coave Therapeutics Business Overview
  28. 6.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  30. 6.5.5 Coave Therapeutics Recent Developments
  31. 6.6 Sysmex Corp
  32. 6.6.1 Sysmex Corp Company Information
  33. 6.6.2 Sysmex Corp Business Overview
  34. 6.6.3 Sysmex Corp Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio
  36. 6.6.5 Sysmex Corp Recent Developments
  37. 6.7 Donanemab
  38. 6.7.1 Donanemab Company Information
  39. 6.7.2 Donanemab Business Overview
  40. 6.7.3 Donanemab Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Donanemab Neurodegenerative Disease CDMO Product Portfolio
  42. 6.7.5 Donanemab Recent Developments
  43. 6.8 Eisai
  44. 6.8.1 Eisai Company Information
  45. 6.8.2 Eisai Business Overview
  46. 6.8.3 Eisai Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Eisai Neurodegenerative Disease CDMO Product Portfolio
  48. 6.8.5 Eisai Recent Developments
  49. 6.9 Fujirebio Holdings
  50. 6.9.1 Fujirebio Holdings Company Information
  51. 6.9.2 Fujirebio Holdings Business Overview
  52. 6.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio
  54. 6.9.5 Fujirebio Holdings Recent Developments
  55. 6.10 GenSight Biologics
  56. 6.10.1 GenSight Biologics Company Information
  57. 6.10.2 GenSight Biologics Business Overview
  58. 6.10.3 GenSight Biologics Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio
  60. 6.10.5 GenSight Biologics Recent Developments
  61. 6.11 Neuropore Therapies
  62. 6.11.1 Neuropore Therapies Company Information
  63. 6.11.2 Neuropore Therapies Business Overview
  64. 6.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio
  66. 6.11.5 Neuropore Therapies Recent Developments
  67. 6.12 Nevrargenics
  68. 6.12.1 Nevrargenics Company Information
  69. 6.12.2 Nevrargenics Business Overview
  70. 6.12.3 Nevrargenics Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Nevrargenics Neurodegenerative Disease CDMO Product Portfolio
  72. 6.12.5 Nevrargenics Recent Developments
  73. 6.13 PPD
  74. 6.13.1 PPD Company Information
  75. 6.13.2 PPD Business Overview
  76. 6.13.3 PPD Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 PPD Neurodegenerative Disease CDMO Product Portfolio
  78. 6.13.5 PPD Recent Developments
  79. 6.14 Samsung Biologics
  80. 6.14.1 Samsung Biologics Company Information
  81. 6.14.2 Samsung Biologics Business Overview
  82. 6.14.3 Samsung Biologics Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio
  84. 6.14.5 Samsung Biologics Recent Developments
  85. 6.15 Sanofi(Vigil Neuroscience)
  86. 6.15.1 Sanofi(Vigil Neuroscience) Company Information
  87. 6.15.2 Sanofi(Vigil Neuroscience) Business Overview
  88. 6.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio
  90. 6.15.5 Sanofi(Vigil Neuroscience) Recent Developments
7 North America
  1. 7.1 North America Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  3. 7.3 North America Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  3. 8.3 Europe Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  3. 10.3 South America Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Neurodegenerative Disease CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst